A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Epilepsy
Epilepsy
Refractory Focal Epilepsy
Seizure
Focal Seizure
Focal Onset Seizure

Interventions

DRUG: RAP-219

Sponsor

Rapport Therapeutics Inc.